Gala Health review

The $179 a month that Gala GLP-1 advertises for compounded tirzepatide is a yearly-subscription rate, and it is a floor rather than a fixed price. The shortest plan the site names anywhere is three months, at $199 a month. There is no published month-to-month rate at all.

Gala is unusually direct about this once you look. The product page prints "From $179/month. All doses included. Yearly subscription." A footnote under the homepage cards says the price is calculated on a yearly subscription plan. And the homepage FAQ gives the other rung outright: access starts at $199 per month with a three-month plan, with final pricing determined at checkout based on the plan and medication you pick. Twelve months at $179 is $2,148; a year bought three months at a time at $199 is $2,388. The annual commitment saves $240, and it costs you the ability to leave after 90 days.

One mechanic is genuinely not published: whether the yearly plan is charged monthly or taken as one payment up front. There is no standalone pricing page — that address is a dead page — and checkout sits behind the health assessment on a separate app domain, so it cannot be read from outside. That is worth resolving before you start, because the difference between twelve charges of $179 and a single charge of $2,148 is the difference between a subscription and a purchase. Note also that "cancel anytime" appears among the included features while the headline rate requires a year; ask how those two fit together.

Semaglutide is on the shelf here, in two forms and at two very different prices. Compounded semaglutide rides inside the same From $179 plan — the product page lists "compounded semaglutide and tirzepatide options" as a feature of that one subscription — so choosing the molecule does not change the number. Separately, Gala sells brand-name Ozempic, FDA-approved semaglutide from Novo Nordisk, at from $1,299 a month as a cash price before any insurance reduction. That is $15,588 across a year at cash rates, and it is a steep step up from the compounded line, but a brand-name route on the same provider is rare and it means switching later does not mean starting over somewhere else.

There is a cheaper rung too. Microdosed compounded GLP-1/GIP, tirzepatide included, is listed at $149 a month on the same yearly-plan footnote, which works out to $1,788 for a year. A Wegovy pill is listed as coming soon with pricing at launch, so there is nothing to price on it yet. Every plan includes the provider visit, free shipping and all doses, and FSA and HSA payments are accepted. Coverage is stated as licensed providers in all 50 states, on two separate pages.

What Gala does not publish is more notable than what it does. The compounding pharmacy is described as a wide network rather than named. No individual clinician is named either — the site points at the schools its doctors trained at instead. And the 50-state claim arrives without a state list to check it against. Gala's own footnote is straight about the core caveat: compounded GLP-1 is not FDA-approved and is sourced from licensed compounding pharmacies. Everything in the compounded line is an injection; there is no oral or sublingual route today.

This is a good fit for someone who has already decided to stay on treatment for a year and wants the lowest committed rate, who needs a provider that can reach their state, and who values having a brand-name path and menopause and hormone care available under the same login. It is a poor fit for anyone testing the water for a month, anyone who wants to know the exact charge schedule before entering an assessment, and anyone who needs a needle-free option. If you are unsure you will last a year, price the three-month plan at $199 and treat $179 as what it is — the reward for a commitment you have not made yet.